Qualigen Therapeutics, Inc. announced that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. QN-302 works by selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may potentially offer a tumor-agnostic clinical approach to treatment. Qualigen received Orphan Drug Designation for the intended treatment of pancreatic cancer in January and clearance from the US FDA to initiate a Phase 1 clinical trial in July of this year.

The QN-302 Phase 1 clinical trial is multi-site, open-label, dose-escalation and dose expansion, safety, pharmacodynamic and pharmacokinetic study of intravenous QN-302 in patients with advanced or metastatic solid tumors". The QN-302 Phase1a clinical trial will be conducted at up to four leading clinics and medical centers in the United States.